Skip to main contentSkip to navigation
Sirius Investors

AKBLF Stock: ALK-Abelló A/S Stock Price, Analysis & Insights

Get live AKBLF stock price $38.89, comprehensive ALK-Abelló A/S stock analysis, charts, news, and expert forecast. Real-time AKBLF stock data and investment insights.

38.89
0.00%Today
AKBLFALK-Abelló A/S • Other OTC • Healthcare
Market Cap
7.83B
Volume
105
52W High
38.89
52W Low
26.99

Loading chart data...

ALK-Abelló A/S (AKBLF) Overview

ALK-Abelló A/S (AKBLF) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, AKBLF trades at $38.89 with a market capitalization of 7.83B . Over the past 52 weeks, AKBLF has traded between $26.99 and $38.89 , with the current price positioned at approximately 100% of this range . The stock currently trades at a...

Key Takeaways

  • Operates in the Healthcare sector (Biotechnology)
  • Market cap: 7.83B
  • Current price: $38.89
  • 52-week range: $26.99 - $38.89
  • P/E ratio: 43.21

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North Americ...

Company Information

CEO
Peter Halling
Sector
Healthcare
Industry
Biotechnology
Employees
2736

Contact Information

Address
Boge Alle 6-8
Country
DK

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 43.2)

Lower volatility stock (Beta: 0.70) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for ALK-Abelló A/S shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for ALK-Abelló A/S
  • Investors should consider how ALK-Abelló A/S fits within their overall portfolio allocation
  • Premium valuation (P/E: 43.2) requires strong growth to justify

Market Cap

7.83B

P/E Ratio (TTM)

43.21

Beta

0.70

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.